Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Covington
Harvard Business School
Express Scripts
US Department of Justice
UBS
Chubb
Chinese Patent Office
Accenture

Generated: June 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,935,731

« Back to Dashboard

Which drugs does patent 7,935,731 protect, and when does it expire?

Patent 7,935,731 protects COLCRYS and is included in one NDA.
Summary for Patent: 7,935,731
Title:Methods for concomitant administration of colchicine and macrolide antibiotics
Abstract: Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
Inventor(s): Davis; Matthew W. (Erwinna, PA)
Assignee: Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Application Number:12/786,921
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,935,731
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,935,731

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa COLCRYS colchicine TABLET;ORAL 022352-001 Jul 29, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,935,731

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,093,298 Methods for concomitant administration of colchicine and macrolide antibiotics ➤ Sign Up
7,601,758 Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares ➤ Sign Up
8,097,655 Methods for concomitant administration of colchicine and macrolide antibiotics ➤ Sign Up
8,093,296 Methods for concomitant administration of colchicine and macrolide antibiotics ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Fish and Richardson
Cerilliant
Julphar
Colorcon
Argus Health
McKesson
Chinese Patent Office
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.